Alamar Biosciences, Inc.

S-1 filed

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to commercialize its proprietary NULISA technology for precision proteomics. The company's ARGO HT System, launched in 2024, has achieved rapid adoption with over 300 customers and a growing installed base. Revenue grew to $74.2M in 2025, driven by instrument sales and consumables. The company plans to submit the ARGO HT/DX IVD platform for FDA approval in 2027 and continues to develop collaborations for neurodegenerative disease biomarker research. Alamar emphasizes its focus on enabling early disease detection through high-sensitivity, multiplexed proteomic analysis.

DRS/A amended

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of its common stock, with the offering price expected to be between $X and $X per share. The company aims to list its shares on [exchange] under the ticker symbol 'ALMR,' contingent on regulatory approval. As an emerging growth company and smaller reporting company, Alamar may utilize reduced reporting requirements post-IPO. The filing emphasizes the high-risk nature of investing in its securities, with risks including dependence on its NULISA technology platform, regulatory approvals, and market acceptance of its proteomics solutions.

DRS/A amended

Alamar Biosciences, Inc. filed an amended registration statement (DRS/A) for its initial public offering (IPO), updating disclosures compared to its earlier DRS filing. The filing highlights the company's emerging growth status, plans to list on a stock exchange under the symbol 'ALMR,' and contingencies around listing approval. The amendment includes updated section pagination and references to future financial disclosures, with no material financial data provided yet.

DRS filed

Alamar Biosciences, Inc. is preparing for its initial public offering (IPO) of common stock, with shares expected to be sold at an undisclosed price range. The offering is contingent on listing approval on a stock exchange under the ticker symbol 'ALMR'. The company, an emerging growth company and smaller reporting company, has not previously had a public market for its stock. The filing includes underwriters such as J.P. Morgan and BofA Securities, with proceeds intended for general corporate purposes. The prospectus highlights risks associated with the offering, including the lack of historical liquidity and the need for regulatory approvals.